Analyst Insights

UBS Analyst Hikes Alcoa Price Target But Stays Cautious

In a research note released Thursday, UBS analyst Brian MacArthur maintained a Neutral rating on shares of Alcoa Inc. (AA), but raised his price target to $15.

Wedbush Reiterate Outperform On Dollar General Following The Retirement Of CEO

In a research note released Friday, Wedbush analyst Joan Storms maintained an Outperform rating on shares of Dollar General Corp. (DG), with a price target of $68, following the retirement …

Nike: We Await A Better Entry Point, Says Wedbush Analyst

In a research note released Friday, Wedbush analyst Corinna Freedman maintained a Neutral rating on shares of Nike Inc. (NKE) and raised her price target to $80.

Wedbush Reiterates Outperform On La Jolla As Multiple Catalysts Remain in 2014

In a research note issued Thursday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on La Jolla Pharmaceutical Co. (LJPC) and a price target of $34.

William Blair Maintains Outperform On Citrix Systems As Templeton Continues As CEO

In a research note released Friday, analyst Bhavan Suri of William Blair maintained an Outperform rating on shares of Citrix Systems, Inc. (CTXS) following yesterday’s news that Mark Templeton will …

William Blair Maintains Outperform On Genpact Limited Following New CFO Appointment

In a research note released today, William Blair analyst Anil Doradla maintained an Outperform rating on shares of Genpact Limited (G) following today’s news that Edward J. Fitzpatrick has officially …

Francesca’s Holdings: We See Limited Downside From These Levels, Says William Blair

In a research note released today, William Blair analyst Amy Noblin maintained an Outperform rating on shares of Francesca’s Holdings Corporation (FRAN) following meetings with CFO Mark Vendetti. Noblin noted, “While comp …

Canaccord Maintains Buy On Thoratec Following The Launch Of HeartMate III Trial

In a research note published Friday, Canaccord analyst Jason Mills maintained a Buy rating on Thoratec Corp. (THOR) with a price target of $37.

Canaccord Raises PT To $76 On Nike Following F4Q 2014 Results

In a research report issued Friday, Canaccord analyst Camilo Lyon reiterated a Hold rating on shares of Nike, Inc. (NKE) and increased his price target to $76 (from $71) following Nike’s …

Analyst Corey Davis Of Canaccord Takes A Bullish Stance On Endo International

In a research report released Thursday, Canaccord analyst Corey Davis initiated coverage with a “Buy” rating on Endo International (ENDPׁׂ) and a price target of $83.00 a share, representing a potential upside of …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts